peramivir and Respiratory-Insufficiency

We aimed to study factors influencing outcomes of adults hospitalised for seasonal and pandemic influenza.  Individual-patient data from three Asian cohorts (Hong Kong, Singapore and Beijing; N=2649) were analysed. Adults hospitalised for laboratory-confirmed influenza (prospectively diagnosed) during 2008-2011 were studied. The primary outcome measure was 30-day survival. Multivariate Cox regression models (time-fixed and time-dependent) were used. Patients had high morbidity (respiratory/nonrespiratory complications in 68.4%, respiratory failure in 48.6%, pneumonia in 40.8% and bacterial superinfections in 10.8%) and mortality (5.9% at 30 days and 6.9% at 60 days). 75.2% received neuraminidase inhibitors (NAI) (73.8% received oseltamivir and 1.4% received peramivir/zanamivir; 44.5% of patients received NAI ≤2 days and 65.5% ≤5 days after onset of illness); 23.1% received systemic corticosteroids. There were fewer deaths among NAI-treated patients (5.3% versus 7.6%; p=0.032). NAI treatment was independently associated with survival (adjusted hazard ratio (HR) 0.28, 95% CI 0.19-0.43), adjusted for treatment-propensity score and patient characteristics. Superinfections increased (adjusted HR 2.18, 95% CI 1.52-3.11) and chronic statin use decreased (adjusted HR 0.44, 95% CI 0.23-0.84) death risks. Best survival was shown when treatment started within ≤2 days (adjusted HR 0.20, 95% CI 0.12-0.32), but there was benefit with treatment within 3-5 days (adjusted HR 0.35, 95% CI 0.21-0.58). Time-dependent analysis showed consistent results of NAI treatment (adjusted HR 0.39, 95% CI 0.27-0.57). Corticosteroids increased superinfection (9.7% versus 2.7%) and deaths when controlled for indications (adjusted HR 1.73, 95% CI 1.14-2.62). Early NAI treatment was associated with shorter length of stay in a subanalysis. NAI treatment may improve survival of hospitalised influenza patients; benefit is greatest from, but not limited to, treatment started within 2 days of illness. Superinfections and corticosteroids increase mortality. Antiviral and non-antiviral management strategies should be considered.

Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir

Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Therapy, Combination; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Pneumonia, Viral; Respiratory Insufficiency; RNA, Viral

Topics: Acids, Carbocyclic; C-Reactive Protein; Critical Illness; Cyclopentanes; Diabetic Nephropathies; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Middle Aged; Neuraminidase; Respiratory Insufficiency